STAT

An anarchist takes on the drug industry — by teaching patients to make their own meds

Michael Laufer published blueprints for a homemade "EpiPencil" and is now working on a kit to let patients make other medicines at home — patents be damned.

MENLO PARK, Calif. — The anarchist grew animated as he explained his plan to subvert a pillar of global capitalism by teaching the poor to make their own medicines — pharmaceutical industry patents be damned.

Then he took another sip from a flute of Taittinger Champagne.

Swaggering, charismatic, and complex, Michael Laufer has become a fixture in the growing biohacker movement ever since he published plans last year for a do-it-yourself EpiPencil — a $35 alternative to the pricey EpiPen.

It’s not clear whether anyone has actually ever used a homemade EpiPencil to prevent anaphylactic shock. But that seems almost an afterthought to Laufer’s bigger goal — trying to build a DIY movement to attack high pharma pricing and empower patients.

The de facto leader behind the leaderless collective Four Thieves Vinegar, Laufer is now on to his next project: He’s developing a desktop lab and a recipe book meant to equip patients to cook up a range of medicines, including a homemade version of the expensive hepatitis C drug Sovaldi, on their kitchen counters.

Health professionals have strenuously warned against DIY pharmaceuticals, but Laufer sees his work as a moral crusade against the patent laws and market forces that let drug companies price

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A GLP-1 Side Effect, U.K. Clinical Trial Transparency, And More
A new study links GLP-1 drugs like Ozempic to a higher risk of aspiration pneumonia — a lung infection caused by food breathed into the lungs — after endoscopies.
STAT1 min read
STAT+: Medicare Expected To Negotiate Obesity Drug Prices Soon, New Analysis Predicts
Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An AstraZeneca Deal, A WHO Pandemic Pact, And More
AstraZeneca agreed to acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on targeted radiation therapies for cancer.

Related Books & Audiobooks